Battleground Herceptin: Biocon, Mylan Take Roche Head On With Appeal In Delhi Court
This article was originally published in PharmAsia News
Executive Summary
After being stung by a restraining order related to regulatory approval for biosimilar versions of Herceptin, Biocon and Mylan are appealing a Delhi Court decision that favored Roche.